MedPath

The Effects of Chicken Extract on Mental Energy in Healthy Adults and the Underlying Mechanisms

Not Applicable
Not yet recruiting
Conditions
Healthy Adults
Interventions
Dietary Supplement: Chicken extract supplement (low-dose)
Dietary Supplement: Chicken extract supplement (high-dose)
Other: Placebo
Registration Number
NCT06021223
Lead Sponsor
Brand's Suntory Asia
Brief Summary

This exploratory trial investigates the effect of a chicken extract supplement on mental energy and its potential underlying mechanisms of action among healthy adults using a randomized, double-blind, placebo-controlled clinical trial design. Mental energy is a multi-dimensional construct comprising transient feelings about fatigue, vigor and motivation and cognitive performance in terms of sustained attention and reaction time.

A sub-study investigates the immediate biochemical changes after taking chicken extract.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
189
Inclusion Criteria
  • Male or female at 35-64 years of age
  • Assessed by investigator to be in good health
  • Normal cognition based on investigator's clinical judgement per the routine practice
  • Modified PSQI score > 5
  • Agree to participate in the study and provide written informed consent
  • Agree to abstain from herbal extracts or dietary supplements throughout the study period
Exclusion Criteria
  • BMI < 18.5 or ≥ 27 kg/m2
  • Concurrent pharmacological treatments
  • Current systemic diseases or current/history of neurological or cerebrovascular diseases
  • Active peptic ulcer, or a history of peptic ulcer within the last 2 years
  • Medications or interventions in the last 4 weeks, which in the investigators' judgement could potentially affect the outcome measures
  • Regular significant quantities of dietary supplements or herbal extracts (> 2 times a week) in the last 4 weeks
  • Regular excessive caffeine consumption, heavy alcohol consumption or heavy habitual smokers
  • Any drastic changes in lifestyle (including diet, smoking, sleep, exercise, and mental and physical activities) in the last 4 weeks
  • Not able to maintain the same lifestyle throughout the study period
  • Inadequate visual and auditory acuity to allow neuropsychological testing per investigator's judgment
  • Inability to undergo fMRI scan
  • Any consumption of chicken extract supplement, or carnosine or anserine supplement, in the preceding 4 weeks
  • History of allergy to caseinate, milk, or chicken meat
  • Women who are pregnant or lactating or intending to do so
  • Current enrolment in another interventional study
  • Subjects who show unstable sleep habits during the previous month
  • Excessive blood donation or blood drawn prior to baseline

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Chicken extract supplement (low-dose)Chicken extract supplement (low-dose)140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
Chicken extract supplement (high-dose)Chicken extract supplement (high-dose)140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
PlaceboPlacebo140ml of placebo (caesinate) to be consumed daily for 2 weeks
Primary Outcome Measures
NameTimeMethod
Fatigue assessed by visual analogue scale (VAS)Daily from baseline to Day 14

VAS scores range from 0 to 100, with higher score indicating greater fatigue.

Vigor assessed by visual analogue scale (VAS)Daily from baseline to Day 14

VAS scores range from 0 to 100, with higher score indicating greater vigor.

Reaction time assessed by Deary-Liewald reaction time taskAt baseline and on Day 14
Sustained attention assessed by trail making testAt baseline and on Day 14
Vigor assessed by Profile of Mood States (POMS)Daily from baseline to Day 14

POMS-vigor scores range from 0 to 28, with the higher score indicating greater vigor.

Plasma carnosineAt baseline and on Day 14
Plasma anserineAt baseline and on Day 14
Reaction time and sustained attention (composite) assessed by Cogstate Brief Battery (CBB)At baseline and on Day 14
Plasma global metabolome (metabolic profile) using liquid chromatography mass spectrometry (LCMS)At baseline and on Day 14

Plasma samples will be analyzed to putatively identify biomarkers of product intake by comparison of test group with control group using high-performance liquid chromatography coupled to mass spectrometer (LCMS). LCMS analysis allows the simultaneous and non-targeted analysis of a wide array of endogenous and exogenous metabolites.

Salivary cortisol levelAt baseline and on Day 14
Plasma beta-alanineAt baseline and on Day 14
Sustained attention assessed by psychomotor vigilance testAt baseline and on Day 14
Fatigue assessed by Profile of Mood States (POMS)Daily from baseline to Day 14

POMS-fatigue scores range from 0 to 24, with higher score indicating greater fatigue.

Plasma methylhistidineAt baseline and on Day 14
Motivation assessed by visual analogue scale (VAS)Daily from baseline to Day 14

VAS scores range from 0 to 100, with higher score indicating greater motivation.

Cerebral blood flow using arterial spin labelling magnetic resonance imaging (MRI)At baseline and on Day 14
Cerebral oxygenation using functional MRI blood oxygenation level dependent (BOLD) imagingAt baseline and on Day 14
Whole body metabolic rate using indirect calorimetryAt baseline and on Day 14

Resting body metabolic rate will be measured

Plasma L-histidineAt baseline and on Day 14
Secondary Outcome Measures
NameTimeMethod
Sleep quality measured by modified Pittsburgh Sleep Quality Index (PSQI)At baseline and on Day 14

In the PSQI, scores from the individual items are used to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score, with a range of 0-21 points, with higher scores indicating poorer sleep quality. The modified PSQI measures the sleep quality in the past two weeks.

Trial Locations

Locations (1)

Taipei Medical University Hospital Shuang Ho Hospital

🇨🇳

New Taipei City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath